AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

Job Trends

11 Companies Hiring in California

Looking for a biopharma job in California? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.

July 23, 2025

2 min read

Angela Gabriel

Modern tower buildings in financial district on sunny day in Chicago

Job Trends

6 Companies Hiring in Illinois

Looking for a biopharma job in Illinois? Check out the BioSpace list of six companies hiring life sciences professionals like you.

July 17, 2025

1 min read

Angela Gabriel

AbbVie's office in South San Francisco, California

Cancer

AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B

The deal, which involves a $700 million upfront payment, gives AbbVie access to ISB 2001, a clinical-stage first-in-class trispecific antibody currently being tested for certain kinds of multiple myeloma as well as autoimmune indications.

July 10, 2025

1 min read

Dan Samorodnitsky

Podcast

Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More

H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health Secretary Robert F. Kennedy Jr. and a plea from patients with ALS for access to BrainStorm’s NurOwn.

July 9, 2025

1 min read

Heather McKenzie

Pictured: Office building science collage

Career Advice

The Top 12 Companies Hiring in Biopharma Now

Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.

July 3, 2025

1 min read

Angela Gabriel

Podcast

CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP

The high court sides with HHS on HIV PrEP drugs; Health Secretary RFK Jr.’s newly appointed CDC vaccine advisors discuss thimerosal in flu vaccines, skip vote on Moderna’s mRNA-based RSV vaccine; FDA removes CAR T guardrails; AbbVie snaps up Capstan for $1.2B to end first half; and psychedelics take off again with data from Compass and Beckley.

July 2, 2025

1 min read

Heather McKenzie

Contemporary art collage, female palms in the orange circle, a bag of money. Concept of business and finance.

Mergers & acquisitions

AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies

The all-cash buyout, which gives AbbVie access to Capstan Therapeutics’ in vivo edited CAR T therapy for B cell–mediated autoimmune diseases, adds to a growing sense of momentum in M&A, according to BMO Capital Markets.

June 30, 2025

2 min read

Dan Samorodnitsky

Approvals

Moderna, Merck, UroGen, Score RSV and Cancer Nods in June

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an approval in bladder cancer, and more key regulatory nods from the past month.

June 30, 2025

9 min read

Tristan Manalac